08/06/2021 : Presentation of the webcast that was held following the voluntary hold of clinical studies with masitinib Download PDF Post navigationPreviousPrevious post:Live webcast on Thursday June 3, 2021 following the voluntary hold in the clinical studies of masitinibNextNext post:Summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinibRelated PostsAB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virusNovember 29, 2021AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemiaNovember 22, 2021AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALSNovember 18, 2021AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)October 18, 2021AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)October 4, 2021Revenues for the first half of 2021 and update on AB Science’s activitiesSeptember 30, 2021
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virusNovember 29, 2021
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemiaNovember 22, 2021
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALSNovember 18, 2021
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)October 18, 2021
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)October 4, 2021
